. The crude incidence of malignant melanoma in the European Union is 10/100 000 per year. The incidence increases with latitude, i.e. with increasing prevalence of less pigmented skin types, from 3-5/100 000 per year in Mediterranean countries to 12 -17 in Nordic countries. The mortality is 2.4/100 000 per year with a lesser variation with geography. Increased ultraviolet-B ray exposure seems responsible for an ongoing increase in incidence over recent decades.
Follow-up for localized or locoregional disease
. There is currently no consensus on the frequency of follow-up and recommendations for surveillance testing.
There is insufficient data to recommend regular blood tests, radiological examinations including ultrasound or PET scanning outside of adjuvant treatment or follow-up protocols in patients able and willing to undergo experimental therapy. The following recommendations were judged adequate for most patients by the experts and ESMO faculty: . Patients with sporadic or familial dysplastic naevus syndrome have a high risk and should be followed for life. Sunburns during childhood and unprotected ultraviolet exposure (solar or artificial UV-B rays) are additional risk factors. . Follow-up for 5 years for localized melanoma of < _ 1.5 mm Breslow thickness and for 10 years for others is deemed sufficient despite the rare occurrence of later relapses. . History, physical examination including regional lymph nodes, skin inspection and palpation of primary tumor location every 3 months for 2 years and every 6-12 months thereafter are recommended. . The patient should be instructed in avoidance of sun burns, extended unprotected solar or artificial ultraviolet exposure and in lifelong regular self-examination of the skin and peripheral lymph nodes. 
Note

Levels of Evidence [I-V] and Grades of Recommendation
